FILTERED RESULTS
FILTERS
Ads Top
•
·
·
FILTERED RESULTS
Trump says efforts to extract nuclear “dust” from Iran will take significant time and be...
U.S. and Iran Engage in Heightened Rhetoric Amid Stalled Peace Talks
JPMorgan’s national security initiative to expand in Europe
Exclusive-SpaceX tries to woo Wall Street with three-day analyst meeting this week, sources say
Iran alleges US struck Iranian commercial vessel, demands crew be released – Foreign...
Kevin Warsh Heads for the Hill: A Confirmation Hearing Guide
It Doesn’t Matter What Kevin Warsh Has to Say
EQT Raises $15.6B for Asia Private Equity Fund
Quilter plc sees JPMorgan reduce its price target to 206p from 212p....
Congo to Halt Cash Dollar Use Next Year to Prop Local Unit
Costco Increases Quarterly Dividend by 13%
AI Stocks Expected to Lead Nasdaq Recovery
Microsoft and Meta Prepare for Earnings Reports Amid AI Competition
IBM Set to Release Earnings Report This Wednesday
Fitch Reports Easing of China's Shadow Lending Practices
South Korea Issues 20-Year Government Bonds at 3.610% Yield
New Zealand’s RBNZ sectoral factor model shows inflation at +2.7% YoY in Q1....
Global clean power growth points to permanent shift, analysts say
The big short meets private credit
EQT and Omers to lift funding for struggling broadband group to €5bn
Seoul shares hit record intraday high on back of tech sector rally-NA...
Toby Neugebauer Incredibly Bullish on Project Matador and Calls for Sale of Company to Maximize Shareholder Value
Trump Comments on Challenges of Extracting Nuclear Material in Iran
Renewable Energy Surpasses Global Electricity Demand in 2022
South Korea issues 20-year government bonds at a yield of 3.610%, according to the finance...
Badr Jafar: Private sector must shoulder stability in times of war
Tesla Settles Last-Minute Over Fatal 2018 Model S Crash That Killed Florida Teen
Sanrio Launches Gaming Brand, Tapping Fast-Growing Market
WTI edges higher to near $86.00 on uncertainty over US-Iran talks-FX...
Asia stocks mixed amid Iran uncertainty; KOSPI hits record high on AI rally
China’s youth jobless rate rises to 16.9% in March
South Korean Battery Stocks Rally on Mercedes-Benz Partnership
Indonesia’s equity benchmark edges down 0.5% to 7,550 points at the open....
Three Ships Including an Iranian Vessel Attempt Hormuz Transits
US-Iran Talks Set for Islamabad as Ceasefire Deadline Approaches
Coinbase Faces Legal Challenges Amid Board Restructuring
AST SpaceMobile Faces $2 Billion Market Cap Loss After Satellite Deployment Issue
Lululemon to Open Eight New Stores in Mexico as Part of North American Expansion
Cadence Design Systems Stock Rises Amid Geopolitical Concerns
Snowflake's Fair Value Estimate Reduced Amid AI Growth
Indonesia Exchange Chief Reports MSCI Acknowledgment of Proposals
Japan's Finance Minister Addresses Market Volatility
Middle East crisis: ‘Highly unlikely’ Iran ceasefire will be extended if no deal reached, Trump says
Indonesia exchange chief says MSCI has acknowledged its four proposals, which is...
Indonesia exchange chief says dialogue with global investors continues to strengthen the capital...
Analysis-Once shunned, activist investors dig in to win in Japan
Tim Cook Has Left 'Big Shoes' To Fill, Says Dan Ives — Gene Munster And Sam Altman React To The Handoff And John Ternus's Rise As Apple CEO
CCE 2026 Wrapped Up with Record-Breaking Global Participation and Innovation
AI Boom Propels Kospi to Record as Tech Giants Defy War Jitters
Kymera Therapeutics Secures $45 Million Milestone Payment from Gilead Sciences
Kymera Therapeutics, Inc. has announced that Gilead Sciences, Inc. has exercised its option to exclusively license KT-200, a novel oral CDK2 molecular glue degrader. This development marks a significant milestone for Kymera, as the option exercise triggers a $45 million payment from Gilead.
KT-200 is recognized as a first-in-class candidate in its category, having been discovered and characterized by Kymera. The collaboration with Gilead is expected to advance the development of KT-200, which aims to provide new therapeutic options in the treatment of various diseases.
The licensing agreement underscores the potential of KT-200 and highlights Kymera's role in pioneering innovative therapies in the biopharmaceutical sector. The financial boost from Gilead will support further research and development efforts for this promising candidate.
© 2026 KLEA News. All Rights Reserved. This article is provided for informational purposes only. It is not offered or intended to be used as legal, tax, investment, financial, or other advice.
Source: KLEA News